⚡ Quick Answer — What is Triohale Rotacaps?
Triohale Rotacaps is een triple-therapy inhaler for severe COPD and difficult asthma, combining three molecules in one device: tiotropium (LAMA), formoterol (LABA), and ciclesonide (ICS). Triple therapy targets all three modifiable mechanisms of obstructive airways disease: parasympathetic tone, smooth-muscle β2 deficiency, and airway inflammation. Used as twice-daily maintenance in COPD with frequent exacerbations. Each rotacaps delivers tiotropium 18 mcg + formoterol 12 mcg + ciclesonide 200 mcg per rotacap, geproduceerd door Cipla at WHO-GMP certified facilities.
📦 Elke bestelling is gedekt door onze Reshipment Assurance Policy — als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.
Waarom bestellen bij MedsBase
Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen — geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor — nooit “MedsBase” of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.
What Is Triohale Rotacaps?
Triohale Rotacaps is one of the few three-in-one fixed-dose triple-therapy inhalers available in India. Major international triple combinations include Trelegy Ellipta (fluticasone furoate + umeclidinium + vilanterol; GSK), Trimbow (beclomethasone + formoterol + glycopyrronium; Chiesi), and Breztri Aerosphere (budesonide + glycopyrrolate + formoterol; AstraZeneca). Triohale Rotacaps is conceptually similar — a single twice-daily inhaler delivering all three mechanism classes.
How Does Triohale Rotacaps Work?
- Tiotropium (LAMA) — blocks M3 muscarinic receptors, relaxing parasympathetic airway tone for 24 hours.
- Formoterol (LABA) — activates β2 receptors for rapid (1–3 min) and sustained (12 h) bronchodilation.
- Ciclesonide (ICS) — a prodrug activated by lung esterases; suppresses airway inflammation. The prodrug design minimises oropharyngeal candidiasis seen with older ICS.
- Combined: reduces exacerbations more than dual therapy in COPD with frequent exacerbations and elevated blood eosinophils (≥100–300/µL), per IMPACT, ETHOS, KRONOS, TRIBUTE landmark trials.
Toepassingen en Indicaties
- Severe COPD with frequent exacerbations on LAMA-LABA dual therapy (GOLD group E)
- COPD with elevated blood eosinophils (≥100/µL) — eosinophilic COPD
- Severe asthma (Step 5 GINA) not controlled by ICS-LABA at high dose
- Asthma-COPD overlap (ACOS) with frequent exacerbations
Triohale Rotacaps Dosage
| Patient | Dosering | Frequentie |
|---|---|---|
| Adults — severe COPD | 1 rotacap | Twice daily |
| Adults — severe asthma (Step 5 GINA) | 1 rotacap | Twice daily |
How to Use Triohale Rotacaps Properly
- Insert one rotacap into the Rotahaler with the coloured end down.
- Twist sharply — listen for the click.
- Breathe out fully away from device.
- Seal lips around mouthpiece.
- Inhale forcefully and deeply; you should hear the rotacap whir.
- Hold breath 10 seconds, then breathe out slowly.
- Check rotacap is empty; repeat if powder remains.
- For ICS-containing combinations: rinse mouth, gargle, and spit out.
Side Effects of Triohale Rotacaps
Vaak voorkomend:
- Dry mouth (anticholinergic)
- Mild tremor or palpitations (β2)
- Mild oral thrush, hoarseness (ICS — minimised by ciclesonide prodrug design and oral rinsing)
- Throat irritation, mild cough on inhalation
- Headache, sinusitis
Minder vaak:
- Constipation, urinary hesitancy
- Acute angle-closure glaucoma (rare; care with mist near eyes)
- Hypokalaemia at high doses (with diuretics, theophylline, oral steroids)
- Pneumonia (slight ICS-related increase in COPD)
- Atrial fibrillation in susceptible older patients
Serious — stop and seek help:
- Severe allergic reaction / anaphylaxis
- Paradoxical bronchospasm
- Acute eye pain, red eye, halos (glaucoma — emergency)
- Acute urinary retention
- Pneumonia signs in COPD users (fever, productive cough, breathlessness change)
Waarschuwingen en voorzorgsmaatregelen
- {$brand} is a controller, not a reliever. Keep a SABA (Asthalin, Levolin) for acute attacks.
- Triple therapy is for selected COPD patients — those with frequent exacerbations on LAMA-LABA, especially with elevated blood eosinophils. Not first-line for newly diagnosed COPD.
- Pneumonia risk: ICS in COPD slightly raises pneumonia risk — ensure ICS adds value (eosinophilic phenotype, frequent exacerbations).
- Glaucoma & prostatism: caution with anticholinergic component.
- Cardiovascular disease: use cautiously with arrhythmias, severe coronary disease.
- Rinse mouth after every dose to minimise oral thrush and hoarseness.
- Zwangerschap: limited data on triple therapy — discuss benefit/risk with prescriber.
Contra-indicaties
- Hypersensitivity to tiotropium, formoterol, ciclesonide, atropine derivatives, or excipients
- Severe lactose / milk-protein hypersensitivity (DPI)
- Untreated active fungal, bacterial, mycobacterial, or viral respiratory infection
- Acute glaucoma — relative
- Severe prostatic obstruction — relative
Geneesmiddelinteracties
| Interacting drug | Effect | Wat te doen |
|---|---|---|
| Strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, clarithromycin) | Increase systemic ICS exposure → adrenal suppression / Cushing risk | Avoid prolonged co-use; monitor cortisol if essential |
| Other inhaled or systemic corticosteroids | Additive HPA-axis suppression | Use lowest effective dose; monitor for systemic steroid effects |
| Live vaccines | Reduced immune response if high-dose ICS | Inactivated vaccines preferred during high-dose use |
Opslag
- Store below 25°C in a dry place. Keep desiccant in the bottle.
- Do not store in the bathroom — humidity makes the powder clump and reduces dose delivery.
- Once the strip/blister is opened, use within the period stated on the leaflet (typically 2–3 months).
- Keep out of reach of children.
Gerelateerde alternatieven op MedsBase
- Foracort Inhaler — budesonide + formoterol ICS-LABA
- Seretide Accuhaler — fluticasone + salmeterol ICS-LABA
- Budecort Inhaler — budesonide ICS preventer
- Duova Inhaler — tiotropium + formoterol LAMA-LABA combo
- Triohale Inhaler — tiotropium + formoterol + ciclesonide triple
Veelgestelde vragen
When is triple therapy indicated?
For COPD with frequent exacerbations on LAMA-LABA (especially with elevated blood eosinophils), or for severe asthma uncontrolled on high-dose ICS-LABA. Not first-line in newly diagnosed COPD or mild asthma.
How is Triohale different from Foracort plus Tiova?
Triohale combines all three molecules in one device — single inhaler, twice daily. Taking Foracort + Tiova achieves a similar pharmacological effect but requires two inhalers (and more compliance burden). Single-device triple has been shown in trials to improve adherence.
How fast does Triohale work?
Formoterol = 1–3 min onset (rapid). Tiotropium and ciclesonide build over hours-to-days. Full benefit at 2–4 weeks.
Is Triohale a reliever?
No — controller only. Keep a SABA (Asthalin, Levolin) for acute attacks.
Why must I rinse my mouth?
Ciclesonide ICS component still warrants oral rinsing to prevent thrush, although ciclesonide produces less oropharyngeal candidiasis than older ICS due to its prodrug design.
Is Triohale safe long-term?
Yes, with regular review. Annual checks for glaucoma, cataracts, urinary symptoms, oral thrush, pneumonia in COPD users.
Pneumonia risk?
ICS in COPD slightly raises pneumonia risk (~1–2% absolute increase in trials). Ensure ICS is needed (eosinophilic phenotype, frequent exacerbations).
Can I take Triohale during pregnancy?
Limited data on triple therapy in pregnancy. Discuss with prescriber; budesonide-based ICS-LABA is preferred where the LAMA can be omitted.
How does Triohale compare to Trimbow or Trelegy?
Trimbow (beclomethasone + formoterol + glycopyrronium, Chiesi) and Trelegy Ellipta (fluticasone furoate + umeclidinium + vilanterol, GSK) are international triple inhalers. Triohale (tiotropium + formoterol + ciclesonide) is the Indian-market triple. Pharmacological class equivalent; molecule choice varies.
Gerelateerde alternatieven
Andere producten in Chronische aandoeningen die klanten ook bekijken:





























Beoordelingen
Er zijn nog geen beoordelingen